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Abstract: Japanese encephalitis (JE) is the leading form
of viral encephalitis in Asia. It is caused by the JE virus
(JEV), which belongs to the family Flaviviridae. JEV is
endemic to many parts of Asia, where periodic outbreaks
take hundreds of lives. Despite the catastrophes it causes,
JE has remained a tropical disease uncommon in the
West. With rapid globalization and climatic shift, JEV has
started to emerge in areas where the threat was
previously unknown. Scientific evidence predicts that
JEV will soon become a global pathogen and cause of
worldwide pandemics. Although some research docu-
ments JEV pathogenesis and drug discovery, worldwide
awareness of the need for extensive research to deal with
JE is still lacking. This review focuses on the exigency of
developing a worldwide effort to acknowledge the prime
importance of performing an extensive study of this thus
far neglected tropical viral disease. This review also
outlines the pathogenesis, the scientific efforts channeled
into develop a therapy, and the outlook for a possible
future breakthrough addressing this killer disease.
Introduction
A disturbing news item that was aired on news channels in
August 2008 reported that the ‘‘kid killer’’ in Uttar Pradesh (UP)
had struck again. Hospitals were flooded with patients, proper
medical treatment was unavailable, and many people died [1].
This has been a very common report coming nearly every year
from UP in northern India, which has become an epicenter for the
killer disease Japanese encephalitis (JE). About 1,000 children die
of this brain fever in UP every year. Statistical records show that
more than 25,000 children have died of JE in the region since
1978, and the disease was started to be treated as a national health
emergency in India in 2007 [2].
JE, one of the leading forms of viral encephalitis worldwide, is
prevalent mostly in eastern and southern Asia, covering a region
with a population of more than 3 billion. The disease affects
mostly children. Around 30,000–50,000 cases of JE and up to
15,000 deaths are reported annually, although these statistics may
be a gross underestimation because of inadequate surveillance and
reporting. About 25%–30% of JE cases are fatal, and 50% result
in permanent neuropsychiatric sequelae [3].
Generous efforts are being made by developed countries to deal
with the grave conditions of JEV outbreaks in Asia [4,5].
Unfortunately, the Western world is still underestimating the
possibility of emergence of JE in the West [6]. JE is being treated
as a rare and exotic disease and is not given priority in
international public health programs [7]. This review outlines
the pathogenesis of and the therapeutic prospects for JE and
focuses on the exigency of developing a worldwide effort to
acknowledge the prime importance of performing an extensive
study of this neglected tropical disease.
Ecology
JE virus (JEV) ecology has been widely studied. The virus exists
in a zoonotic transmission cycle among mosquitoes, pigs, bats, and
water birds belonging to the family Ardeidae (cattle egrets and
pond herons). Humans become infected when bitten by an
infected mosquito and are a dead-end host because of low viremia,
preventing the virus from being transmitted further [8]. The major
mosquito vectors of JEV vary in different geographic regions; the
most common are those of the Culex genus [9,10]. Pigs are the
main contributors in the transmission cycle with respect to human
infection, because these animals often stay close to human
dwellings. Ardeid birds are important maintenance hosts.
Recently, JEV antibodies were detected in bats, revealing that
bats can be a part of the JEV transmission cycle [11]. Vertical
transmission of JEV in mosquitoes probably explains the
‘‘overwintering’’ of virus between epidemics [10]. JEV infection
in domestic animals and other vertebrate species such as equines
does not result in high viremias; thus, they are not expected to
transmit the virus to humans [12]. Amphibians and reptiles can be
infected experimentally, but their role in overwintering and
maintenance in the environment is not known [13].
Origin and Spread
JEV was first isolated in Japan in 1935 but had been described
there as early as 1870 [14]. JEV evolved from its ancestral
flavivirus form into its present form in the Indonesia–Malaysia
region. From there, it has spread to northward and westward
directions in Asia and recently has been isolated in Australia [15–
17]. To date, the PrM and E protein encoding genes have usually
been used for the phylogenetic analysis of JEV [17]. Five
genotypes of JEV are known at present. Different genotypes of
JEV (associated with different virulence patterns) thrive in a
particular climatic condition: genotypes IV (the oldest) and V are
isolated in the tropical endemic region of Indonesia–Malaysia,
whereas genotypes III and I are found in the epidemic regions
[18,19]. During the 1995 outbreak in Torres Strait, it was thought
that JEV moved with the vagrant birds from island to island, from
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subsequent spread of JEV into northern mainland Australia was
suggested to be through the movement of infected mosquitoes
blown by cyclonic winds [13,20,21]. The spread of flaviviruses
such as JEV also seems to correlate with rapid globalization, the
population explosion, and changes in global climatic condition due
to industrialization and deforestation [22] (Figure 1).
According to a report published by the US Centers for Disease
Control and Prevention [23], researchers believe that flaviviruses
such as the West Nile virus (WNV) could have entered the West
through infected travelers, unintentional introduction of infected
birds, and/or virus-bearing mosquitoes. Thus, there is a high
probability for such spread in the case of JEV [6].
Clinical Manifestations
The manifestations of the disease depend on which part of the
nervous system is affected and include early symptoms, such as
nonspecific febrile illness, viz. diarrhea and rigor, followed by
symptoms such as reduced levels of consciousness, seizures,
headache, photophobia, and vomiting in the next stage [14]. In
some cases, abnormal mental conditions may be observed. Later
symptoms also include poliomyelitis-like flaccid paralysis [24] and
parkinsonian syndrome, which manifests the classic description of
JE—dull, flat, mask-like face with wide, unblinking eyes; tremor;
generalized hypertonia; cogwheel rigidity; and other abnormalities
in movement [14]. Severe encephalitis is associated with a higher
frequency of seizures [8]. In fatal cases, patients ultimately slip into
an acute coma. Various electroencephalographic abnormalities
include the presence of alpha, theta, and delta coma, and
epileptiform conditions [14,25]. Symptoms of brainstem infection
include changes in the respiratory pattern, flexor and extensor
posturing, and abnormalities in the papillary and occulocephalic
reflexes [14,26]. In fatal cases of JEV, pathological changes are
polymorphic and diffuse, involving various parts of the nervous
system where the brain shows a severe degree of vascular
congestion, microglial proliferation, formation of gliomesenchymal
nodules, focal or confluent areas of cystic necrosis, cerebral edema,
and transcompartmental shift [10,27]. Many survivors of JE
acquire neuropsychiatric sequelae with cognitive and language
impairment, in which case the disease presents itself not only as a
killer but also as a cause of an immense social and financial
burden, especially for a developing country [3,28–30].
Pathogenesis
A myriad of factors govern the severity of JEV pathogenesis
(Figure 2). The failure of the host to produce antibodies against the
virus is associated with an increased likelihood of the disease to
turn lethal [31]. Crossing the blood–brain barrier is an important
factor in the increased pathogenesis and clinical outcome of the
neurotropic viral infection [32]. After entering the body through a
mosquito bite, the virus reaches the central nervous system (CNS)
via leukocytes (probably T lymphocytes), where JEV virions then
bind to the endothelial surface of the CNS and are internalized by
endocytosis [33]; however, it is still not clear whether macrophages
and B lymphocytes can also harbor JEV. In other flaviviral
infections, such as WNV, macrophages could serve as a reservoir,
spreading the virus from the peripheral areas to the CNS [34].
Studies have shown that WNV is capable of entering the CNS
through anterograde axonal transport [35]. Because both WNV
and JEV belong to the same family of viruses [36–38],
Figure 1. The global distribution of JEV genotypes. See [15–19]. The shaded areas indicate the present distribution of JEV, whereas the arrows
indicate the areas where there is a high possibility of virus spread due to globalization and climatic change.
doi:10.1371/journal.pntd.0000437.g001
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pathogenesis; however, convincing evidence is still lacking.
JE typically develops in patients after an incubation period of 5–
15 days. It is possible that during this time, the virus resides and
multiplies within host leukocytes, which act as carriers to the CNS.
T lymphocytes and IgM play a major role in the recovery and
clearance of the virus after infection [31]. A plausible therapy of
clearing the virus load while in its incubation period in peripheral
lymphatic tissues and spleen may actually prevent JEV pathogen-
esis. Besides neuronal cells, researchers have shown that astrocytes
are also infected by JEV [18]. Astrocytes, being a component of
the blood–brain barrier, may help in the transmission of JEV from
peripheral tissues to the cerebrospinal fluid.
The molecular pathogenesis of JEV infection is still unclear. It is
known that JEV causes neuronal cell death in two ways—direct
neuronal killing [39], wherein viral multiplication within neuronal
cells leads to cell death, and the indirect mode of killing, wherein
massive inflammatory response causes an up-regulation of reactive
oxygen species and cytokines such as tumor necrosis factor a
(TNFa), which, in turn, causes neuronal death [40]. The key factor
in indirect neuronal cell death during JE is the uncontrolled
overactivation of microglia cells [40], which release proinflamma-
tory cytokines such as interleukin 6 (IL-6), TNFa monocyte
chemotactic protein 1 (MCP1), and RANTES (regulated upon
activation, normal T cell expressed and secreted), promoting
massive leukocyte migration and infiltration into the brain [41].
The production of interferon-c–inducible protein 10 (IP-10) by
activated astrocytes also contributes to the infiltration of natural
killer cells and monocytes, among others [42]. Although nitric oxide
(NO) plays an important role in inflammation during JE infection,
NO itself is a very strong antimicrobial agent, and researchers have
shown that it profoundly inhibits viral RNA synthesis, viral protein
accumulation, and virus release from infected cells [43]. Thus, NO
may play a crucial role in the innate immunity of the host and its
ability to restrict the initial stages of JEV infection in the CNS. On
the other hand, dysregulation of NO secretion may inflict a similar
but toxic effect on uninfected host cells, thereby actually
contributing to the pathogenesis of encephalitis.
Neuronal death by secreted TNF is mediated by the TNF
receptor–associated death domain protein (TRADD) [44], which
thereupon regulates a downstream apoptotic cascade in neurons.
However, neuronal death also activates microglia and astrocytes;
thus, the inflammatory cycle goes on.
The role of astrocytes in the pathogenesis of JE remains unknown.
Research has shown that JEV infection differentially modulates the
induction pattern of reactive oxygen species, IL-6, IL-8, IL-1, MCP-1,
RANTES, and MIG secretions in different astrocytic cell lines [45].
Nevertheless, increased astroglial activation also has homeostatic
implications as it enhances the ability of astrocytes to detoxify
glutamate, inactivate free radicals, and produce neurotrophic factors,
although it is not sufficient in conferring protection against JEV-
mediated pathogenesis [46]. In vivo studies have reported that there is
a progressive decline in the level of the anti-inflammatory cytokine
IL10 following viral infection [47]. Thus, the intense cascade of
proinflammatory mechanism takes over the homeostatic mechanism,
leading to the pathogenesis of encephalitis.
Reports suggest that JEV infection affects neuronal progenitor
cells (NPCs) in the subventricular zone and severely compromises
their ability to proliferate. JEV infection does not result in the
death of resilient NPCs, but the cycling ability of these cells is
suppressed [48]. This arrested growth and proliferation of NPCs
might be the cause of neurological consequences in children
Figure 2. Events that lead to the establishment of JE pathogenesis.
doi:10.1371/journal.pntd.0000437.g002
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transplacentally [49–51], by which means the virus could affect the
normal neuronal development of the fetus.
Diagnosis
Patients with JE present vivid signs of acute encephalitic
syndrome. There are many possible causes of acute encephalitic
syndrome; thus, laboratory confirmation is essential for the accurate
diagnosis ofJE,whichisnota simple process because oftheverylow
viremia. Diagnosis is therefore targeted toward the detection of
antibodiesinserumandcerebrospinal fluid.Casesofcross-reactivity
of antibodies to other flaviviruses cause confusion in the diagnosis of
JEV. The World Health Organization (WHO) has drawn up
surveillance standards for the detection of JEV, recommended case
definitions of JE, and set up criteria that are to be fulfilled to
diagnose a case as JE [52]. IgM capture ELISA has been the most
widely used diagnostic method for JE detection [53,54]. At present,
much advancement has been achieved in methods for the early
detection of JEV; examples are the dipstick method [55], JEV-
CheX [56], and reverse transcriptase PCR [57].
Treatment
Interferon therapy has not met with great success [58]. A recent
clinical trial of oral ribavarin administration was also not
encouraging [59]. Naturally occurring compounds such as
arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, and
rosmarinic acid, a phenolic compound found in various Labiatae
herbs, render protection to mice against JEV of the GP78 strain by
markedly decreasing JEV-induced neuronal apoptosis, microglial
activation, active caspase activity, and induction of proinflamma-
tory mediators in the brains of the infected animals [60,61].
A notable breakthrough in antiflaviviral drug research is the
discovery of minocycline, a member of the broad-spectrum
antibiotic tetracycline group, as an antiviral drug [62]. A
significant piece of research on minocycline as an anti-JEV drug
is an in vivo study [38] that showed that minocycline reduces
neuronal apoptosis, microglial activation, active caspase activity,
proinflammatory mediators, and viral titer markedly on the 9th
day after infection. Another compound that has shown inhibition
of JEV replication completely in vitro is an N-methylisatin-b-
thiosemicarbazone derivative [63].
Glucosidase inhibitors of the endoplasmic reticulum, such as N-
nonyl-deoxynojirimycin, which block the trimming step of N-
linked glycosylation, have been shown to eliminate the production
of several endoplasmic reticulum–budding viruses, including
dengue type II (DEN-2) and JEV [64].
In an innovative study on mice using RNA interference, a single
intracranial administration of lentivirus-delivered short hairpin
RNA or lipid-complexed small interfering RNA (siRNA) before
viral challenge or siRNA treatment after viral challenge was
sufficient to provide protection against lethal encephalitis.
Interestingly, when a cross-species conserved sequence of cd-loop
coding viral envelope protein was targeted, encephalitis following
both JEV and WNV challenge was avoided. This result clearly
indicates that by careful drug design of the conserved target site, a
single siRNA treatment could suppress viral infection across
species, thereby augmenting the treatment of acute viral infections
with overlapping clinical symptoms [65].
Protection
One of the most important aspects of the prevention of JE
spread is vector control. Paddy fields not only provide an ideal
breeding ground for mosquitoes but also attract migratory birds,
thereby helping the spread of the virus. Larvicides, insecticides,
and ecofriendly methods such as using neem cakes and growing
larvivorous fish are useful in controlling mosquitoes in paddy fields
[9]. Vaccinating pigs is also a logical way to acquire protection
against JEV by breaking the mosquito–pig–human transmission
cycle [66]. Human vaccination is considered to be the most
effective control measure for JEV. It is necessary to protect not
only the residents of endemic regions but also others such as
international tourists visiting rural Asia, where there is a growing
risk of transmission of JEV to travelers, thus increasing the need
for pretravel immunization with an effective vaccine product.
Multiple vaccines exist to control JE, but all have limitations.
Unfortunately, unlike smallpox, it is very difficult to eradicate JEV
by vaccination, because human beings are actually a dead-end
host of the virus.
The formalin-inactivated vaccine against JEV was produced
from infected mouse brain–derived tissue soon after the virus was
discovered. This type of vaccine became commercially available in
Japan (as the Japanese Biken vaccine [JE-VAX]) and in Korea (as
the Korean Green Cross vaccine) and was produced also in the
United States [67]. This is the only WHO-recommended vaccine,
but there are several concerns with its side effects [68,69].
Moreover, the vaccine is expensive and requires multiple doses to
maintain efficacy and immunity. This makes its use difficult for
people in developing countries. Researchers have been trying to
avoid a multidose requirement of the vaccine by using adjuvants
such as biodegradable poly(gamma-glutamic acid) nanoparticles
and aluminum [70].
In 1988, an inexpensive, live attenuated vaccine (SA 14-14-2)
[71] was licensed by China. However, WHO does not approve it
for human use because it is raised in primary kidney hamster cells.
Initially, this vaccine was used almost exclusively in China and
parts of Korea, but it is now widely used in the Indian
subcontinent. The vaccine seems to be highly effective, and very
few adverse effects have been observed [72]. The recently
developed Vero cell–derived inactivated JE vaccine containing
the purified, inactivated JEV strain SA 14-14-2 with aluminum
hydroxide as adjuvant seems to be a promising candidate and has
passed the Phase III randomized controlled trial [73].
Several efforts have been made to develop recombinant
vaccines for JEV [3]. One study described a recombinant vaccinia
virus expressing viral structural proteins. Later, a highly attenuated
recombinant vaccinia virus, NYVAC [74], was used for JE vaccine
development, and this proved quite successful [75]. Other strains
tested include modified vaccinia virus Ankara strain [76,77]. Later
studies focused on safe replication-competent recombinant viruses
such as avipoxviruses and ALVAC, which infect cells but do not
replicate [74,77,78]. Again, in a research on peptide-based
vaccine, Johnson grass mosaic virus coat protein was fused with
JEV E protein by using recombinant DNA technology [79].
Researchers have also constructed the yellow fever virus to
express JEV protein, the most promising recombinant vaccine
under development. It is widely known as Chemeri-Vax-JE, in
which the structural protein (PrM and E) of the JEV SA14-14-2
strain was inserted into YF17D [80–82]. In vivo studies have
shown that passive immunization with monoclonal antibodies
against different epitopes of JEV E protein protects against JEV-
mediated cell death in mice [83].
Researchers have also tried DNA vaccination for JE in rhesus
monkeys [84]. In one study, a single intramuscular injection of
recombinant plasmid DNA containing JEV PrM and E genes
induced protective immunity and prevented JE in mice and their
progeny [85]. Again, investigators have used both intramuscular
www.plosntds.org 4 September 2009 | Volume 3 | Issue 9 | e437injection and a gene gun to deliver the plasmid gene for E protein
and PrM protein [86]. DNA immunization with colloidal gold,
construction of chimeric DNA vaccine vectors, and DNAzymes are
the focus of some of the other recent promising studies [87–89].
Future Perspectives
Flaviviral drug research is moving at an expeditious pace. We
are hopeful that a dependable chemotherapeutic agent will soon
be at hand to abrogate the flaviviral diseases. Fortunately,
although JEV is presently under the radar of big, ambitious
drug-design projects, owing to the conserved nature of the
flaviviral proteins, research that has concentrated on WNV,
hepatitis C virus (HCV), dengue virus (DENV), and others could
be extrapolated to come up with a JEV-specific drug design.
Efforts are being channeled into the design of a future drug
against the NS2B and NS3 nonstructural proteins of flaviviruses
such as WNV. This design focuses on crucial physicochemical and
biochemical properties of proteases by using crystallography-based
models of NS3 substrate interaction compounds [90]. Scientists
are also trying to target the flaviviral capping enzyme [91,92].
The E and NS5 proteins of flaviviruses are also a very promising
target for future drug designs. Research has elucidated the crystal
structure of the enzymatically active domains of these proteins’
inhibitor to understand its biochemical properties, subcellular
localization, and regulation, thereby helping to design specific
inhibitors that would alter the kinetics of these proteins and thus
viral production [93–95].
Advances in our knowledge of the molecular biology of
flaviviruses and construction of a flavivirus replicon system have
paved the way for high-throughput screening of flaviviral
inhibitors in an elaborate collaborative project using the mega-
computing power of World Community Grid [96]. Researchers
are conducting extensive calculations to identify new drug-like
molecules against WNV, yellow fever virus, DENV, and HCV, by
using binding calculations, mean-field molecular dynamics
algorithms, Autodock virtual docking program, and CHARMM,
a molecular dynamic program. The scale and depth of this project
carry enough promise for a significant breakthrough in flaviviral
drug research.
Finally, studies revealed that different classes of compounds
such as flavonoids, alkaloids, polysaccharides, thiophenes, terpe-
noids, lectins, and lignans, isolated from various plants, have
different antiviral properties and target viral inhibition [97]. More
studies are needed to exploit the potential that natural products
may possess to be developed into anti-JEV drugs.
Conclusion
With cutting-edge technologies of biomedical science at hand,
the future bears hope for a breakthrough in JEV therapy.
Unfortunately, only a handful of laboratories in developed
countries are actually involved in any rigorous study involving
JEV. If not for its similarity with the other flaviviruses such as
WNV, DENV, and HCV, its present research status could have
been worse. The scientific communities all over the world should
be more concerned about the recent emergence of JE in areas of
the world where it was previously unknown. A considerable
percentage of JEV outbreaks occur in developing countries.
Therefore, it is the responsibility of the scientific communities,
federal governments, and WHO to find drugs that could reach the
unprivileged masses. Only then will our scientific efforts be a
success.
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